Pentamidine

Pentamidine (MP-601205) is an antimicrobial agent and interferes with DNA biosynthetics. Pentamidine inhibits parasite Leishmania infantum with an IC50 of 2.5 μM. Pentamidine is a potent and selective protein tyrosine phosphatases (PTPases) and phosphatase of regenerating liver (PRL) inhibitor. Pentamidine has the potential for Gambian trypanosomiasis, antimony-resistant leishmaniasis, and Pneumocystis carinii pneumonia treatment. Antitumor and antibacterial activities[1][2][3][4].

Product Specifications

CAS Number

[100-33-4]

Product Name Alternative

MP-601205

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial; Fungal; Parasite; Phosphatase

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/pentamidine.html

Purity

97.19

Solubility

DMSO : 3.3 mg/mL (ultrasonic; warming; adjust pH to 6 with 1 M HCl; heat to 60°C)

Smiles

N=C(C1=CC=C(OCCCCCOC2=CC=C(C(N)=N)C=C2)C=C1)N

Molecular Formula

C19H24N4O2

Molecular Weight

340.42

Precautions

H302, H315, H319, H335

References & Citations

[2]Nguewa, P.A., et al., Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin. Chem Biodivers, 2005. 2 (10) : p. 1387-400.|[3]Sands M, et al. Pentamidine: a review. Rev Infect Dis. 1985 Sep-Oct;7 (5) :625-34.|[4]David C. Bean, et al. Pentamidine: a drug to consider re-purposing in the targeted treatment of multi-drug resistant bacterial infections? J Lab Precis Med 2017;2:49.|[1]Pathak MK, et al. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther. 2002 Dec;1 (14) :1255-64.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, protect from light)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

Leishmania; Trypanosoma

Citation 01

Biochem Biophys Res Commun. 2019 Sep 17;517 (2) :221-226.|BMC Womens Health. 2022 Nov 24;22 (1) :470.|Drug Des Devel Ther. 2021 Jul 1;15:2857-2868.|Immunity. 2023 Feb 14;56 (2) :272-288.e7.|Int J Mol Sci. 2023 Sep 7;24 (18) :13812.|Microbiol Spectr. 2023 Jun 15;11 (3) :e0313822.|Molecules. 2020 Apr 23;25 (8) :1980.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.